ESAB reports Q2 adjusted EPS $1.21, consensus $1.02

Reports Q2 revenue $720M, consensus $667.88M. “We continue to confidently pursue our strategic vision, consistently driving growth, expanding margins, and improving cash flow,” said CEO Shyam Kambeyanda. “Our global teams continue to harness the transformative power of the ESAB Business Excellence system, propelling us to new heights of efficiency and effectiveness. Our commitment to simplifying product lines has taken root across the enterprise, fueling both growth and profitability. The integration of the Ohio Medical, Swift-Cut and Therapy Equipment acquisitions are on track and performing above expectations. As a result of our strong first half performance and our confidence in our long-term strategy we are raising our full-year 2023 guidance.”